Using the Antigenic Signature of Self-renewing GBM Cells to Target Low & High Mutational Tumor Burden

Time: 9:45 am
day: Conference Day 2


  • Autologous dendritic cells loaded with autologous tumor antigens from self-renewing tumor initiating cells as personal therapeutic cancer vaccines
  • Lessons learned from a single-arm phase 2 trial in primary GBM
  • Randomized, blinded phase 3 trial in primary GBM